Teacher Retirement System of Texas Takes $592,000 Position in Indivior PLC $INDV

Teacher Retirement System of Texas acquired a new position in shares of Indivior PLC (NASDAQ:INDV) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 24,572 shares of the company’s stock, valued at approximately $592,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of INDV. Two Seas Capital LP increased its stake in Indivior by 0.4% in the second quarter. Two Seas Capital LP now owns 11,407,795 shares of the company’s stock valued at $168,151,000 after purchasing an additional 41,018 shares during the period. Goldman Sachs Group Inc. grew its position in Indivior by 18.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock valued at $79,757,000 after buying an additional 1,299,425 shares during the last quarter. Rubric Capital Management LP increased its stake in Indivior by 31.6% in the 2nd quarter. Rubric Capital Management LP now owns 4,647,179 shares of the company’s stock valued at $68,499,000 after buying an additional 1,117,140 shares during the period. Jefferies Financial Group Inc. lifted its stake in shares of Indivior by 47.9% in the 2nd quarter. Jefferies Financial Group Inc. now owns 2,190,274 shares of the company’s stock worth $32,544,000 after acquiring an additional 708,941 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Indivior by 1,122.6% in the second quarter. Geode Capital Management LLC now owns 1,576,915 shares of the company’s stock valued at $23,244,000 after acquiring an additional 1,447,939 shares in the last quarter. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Indivior Trading Down 3.1%

Shares of INDV opened at $34.34 on Thursday. The company has a 50-day moving average of $34.95 and a two-hundred day moving average of $28.32. Indivior PLC has a 12-month low of $7.62 and a 12-month high of $38.00. The stock has a market cap of $4.29 billion, a P/E ratio of 37.33 and a beta of 0.80.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Morgan Stanley reaffirmed an “overweight” rating and issued a $36.00 price objective on shares of Indivior in a report on Wednesday, December 3rd. Weiss Ratings restated a “hold (c)” rating on shares of Indivior in a research note on Wednesday, January 28th. HC Wainwright upped their price objective on Indivior from $35.00 to $48.00 and gave the stock a “buy” rating in a report on Monday, January 12th. Piper Sandler reissued an “overweight” rating and issued a $41.00 target price (up previously from $27.00) on shares of Indivior in a report on Friday, October 31st. Finally, Northland Securities set a $50.00 target price on shares of Indivior in a research report on Tuesday, January 20th. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, Indivior currently has an average rating of “Moderate Buy” and an average price target of $39.33.

Insider Buying and Selling at Indivior

In other news, Director Mark Stejbach purchased 775 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were bought at an average cost of $35.39 per share, with a total value of $27,427.25. Following the purchase, the director directly owned 16,847 shares of the company’s stock, valued at approximately $596,215.33. This trade represents a 4.82% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Keith Humphreys acquired 775 shares of the business’s stock in a transaction dated Monday, January 5th. The stock was purchased at an average cost of $35.39 per share, with a total value of $27,427.25. Following the transaction, the director owned 5,802 shares of the company’s stock, valued at approximately $205,332.78. The trade was a 15.42% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have acquired 4,871 shares of company stock valued at $172,385.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.